195 related articles for article (PubMed ID: 31225929)
1. Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model.
Fuchs S; Bayer M; Taubert R; Manns MP; Pfeilschifter JM; Christen U; Hintermann E
Liver Int; 2019 Dec; 39(12):2330-2340. PubMed ID: 31225929
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6.
Hintermann E; Ehser J; Bayer M; Pfeilschifter JM; Christen U
J Autoimmun; 2013 Aug; 44():49-60. PubMed ID: 23809878
[TBL] [Abstract][Full Text] [Related]
3. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis.
Ehser J; Holdener M; Christen S; Bayer M; Pfeilschifter JM; Hintermann E; Bogdanos D; Christen U
J Autoimmun; 2013 May; 42():39-49. PubMed ID: 23200317
[TBL] [Abstract][Full Text] [Related]
4. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice.
Hintermann E; Ehser J; Christen U
J Vis Exp; 2012 Feb; (60):. PubMed ID: 22331063
[TBL] [Abstract][Full Text] [Related]
5. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 as a model antigen.
Christen U; Holdener M; Hintermann E
Dig Dis; 2010; 28(1):80-5. PubMed ID: 20460894
[TBL] [Abstract][Full Text] [Related]
7. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
9. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.
Maggiore G; Riva S; Sciveres M
Minerva Gastroenterol Dietol; 2009 Mar; 55(1):53-70. PubMed ID: 19212308
[TBL] [Abstract][Full Text] [Related]
11. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
13. Overlap syndrome: autoimmune sclerosing cholangitis.
Thakker A; Karande S
Indian Pediatr; 2010 Dec; 47(12):1063-5. PubMed ID: 21220805
[TBL] [Abstract][Full Text] [Related]
14. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
15. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune hepatitis and overlap syndromes.
Dienes HP; Erberich H; Dries V; Schirmacher P; Lohse A
Clin Liver Dis; 2002 May; 6(2):349-62, vi. PubMed ID: 12122860
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.
Mair M; Zollner G; Schneller D; Musteanu M; Fickert P; Gumhold J; Schuster C; Fuchsbichler A; Bilban M; Tauber S; Esterbauer H; Kenner L; Poli V; Blaas L; Kornfeld JW; Casanova E; Mikulits W; Trauner M; Eferl R
Gastroenterology; 2010 Jun; 138(7):2499-508. PubMed ID: 20193684
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune Hepatitis, Sclerosing Cholangitis, and Autoimmune Sclerosing Cholangitis or Overlap Syndrome.
Kerkar N; Chan A
Clin Liver Dis; 2018 Nov; 22(4):689-702. PubMed ID: 30266157
[TBL] [Abstract][Full Text] [Related]
19. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune sclerosing cholangitis: Evidence and open questions.
Terziroli Beretta-Piccoli B; Vergani D; Mieli-Vergani G
J Autoimmun; 2018 Dec; 95():15-25. PubMed ID: 30366655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
